Metraipolis › archive › dc_79228b73170b

Pregnancy outcomes of patients with retained products of conception following miscarriage treated with relugolix, an oral gonadotropin-releasing hormone… — Europe PMC PMID:41658607

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41658607
DOI
10.3389/fmed.2026.1704529
License (as archived)
solo-consultazione
Archived
2026-11-06T13:15:56.473Z
SHA-256 of the archived text
67147cf0f3830a16ab9db3a403fb52a9b97c66a3389d889c74e577a329e8dc38
Stable URL of this page
https://metraipolis.com/documento/dc_79228b73170b

How to cite

Pregnancy outcomes of patients with retained products of conception following miscarriage treated with relugolix, an oral gonadotropin-releasing hormone… — Europe PMC PMID:41658607 — Europe PMC (en), https://europepmc.org/article/MED/41658607 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_79228b73170b (Metraipolis archive dc_79228b73170b, sha256 67147cf0f3830a16ab9db3a403fb52a9b97c66a3389d889c74e577a329e8dc38)
BibTeX
@misc{dc79228b73170b,
  title = {Pregnancy outcomes of patients with retained products of conception following miscarriage treated with relugolix, an oral gonadotropin-releasing hormone… — Europe PMC PMID:41658607},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41658607},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_79228b73170b; sha256 67147cf0f3830a16ab9db3a403fb52a9b97c66a3389d889c74e577a329e8dc38},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41658607. Agents can read the archived copy with the MCP tool read_document.